Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,069 | $1,725 | $6,608 | $3,681 |
Gross Profit | 882 | 1,537 | 6,542 | 3,676 |
EBITDA | 1,731 | -4,601 | -4,202 | -29,574 |
EBIT | 1,544 | -4,789 | -4,388 | -29,752 |
Net Income | 1,482 | -4,812 | 851 | -29,781 |
Net Change In Cash | 1,069 | 1,725 | 6,608 | 3,681 |
Free Cash Flow | -7,189 | -8,132 | -4,989 | -3,628 |
Cash | 37,355 | 35,939 | 40,791 | 40,463 |
Basic Shares | 261,471 | 261,175 | 230,116 | 228,853 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $14,556 | $9,499 | $8,945 | $14,703 |
Gross Profit | 13,711 | 9,165 | 8,274 | 13,975 |
EBITDA | -67,948 | -17,973 | -22,590 | -25,085 |
EBIT | -68,647 | -18,582 | -23,282 | -25,812 |
Net Income | -63,533 | -18,609 | -21,486 | -26,273 |
Net Change In Cash | 14,556 | 9,499 | 8,945 | 14,703 |
Cost of Revenue | -43,468 | |||
Free Cash Flow | -19,441 | -23,657 | -29,240 | 646 |
Cash | 40,791 | 45,789 | 35,442 | 11,355 |
Basic Shares | 230,116 | 200,193 | 172,663 | 169,792 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.03 |
2026-03-31 | -$0.02 |
2025-12-31 | $0.003 |
2025-09-30 | -$0.13 |